Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

Isis Pharmaceuticals Announces Plan Investigate Higher Dose of ISIS-SMN Rx in Children with Spinal Muscular Atrophy

Share:

Isis Pharmaceuticals (NASDAQ: ISIS) announced today that it plans to add a 12 mg cohort to the ongoing Phase 1b/2a study evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA).  In addition, a 12 mg dose will be included in an open-label extension study for those children who have completed dosing in previous studies.  The addition of the 12 mg cohort will allow for the investigation of this dose in support of the Phase 2/3 registration-directed program planned to begin next year.  

"We are pleased to be able to increase the dose of ISIS-SMNRx based on the safety and tolerability data we have seen to date in both infants and children with SMA.  We have already begun the infant 12 mg dose cohort and look forward to sharing data from this study early next year.  Considering the encouraging safety profile we have observed in children with SMA in the lower dose cohorts, the evaluation of the 12 mg dose will provide additional information as we move into our Phase 3 program.  We are also pleased that after reviewing the data, the FDA agrees that we can proceed in our investigation of a

See full press release

Posted-In: News Guidance Global

 

Related Articles (ISIS)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

UPDATE: J.P. Morgan Downgrades Violin Memory Following Deterioration Of Revenue Model

#PreMarket Primer: Friday, November 22: Draghi Defends ECB Rate Cut